New hope for tough lymphoma: early trial combines novel drug with standard care

NCT ID NCT04161248

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Feb 02, 2026 · Last updated Jun 17, 2026 · Updated 21 times

Summary

This study tests a new drug given together with standard chemotherapy (R-GDP) for people with aggressive B-cell lymphoma that has come back or not responded to treatment. The main goal is to find the highest dose that is safe and does not cause severe side effects. About 40 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

BCCA - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
The Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma follicular lymphoma lymphoplasmacytic lymphoma MALT lymphoma marginal zone lymphoma primary mediastinal large B-cell lymphoma T-cell/histiocyte rich large B cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, B-CELL